Foghorn Therapeutics Inc.
$5.51
▲
0.61%
2026-04-21 06:50:01
foghorntx.com
NGM: FHTX
Explore Foghorn Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$310.52 M
Current Price
$5.51
52W High / Low
$6.95 / $3.27
Stock P/E
—
Book Value
$-1.92
Dividend Yield
—
ROCE
-59.34%
ROE
96.45%
Face Value
—
EPS
$-1.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
106
Beta
3.11
Debt / Equity
-0.38
Current Ratio
2.73
Quick Ratio
2.73
Forward P/E
-5.04
Price / Sales
8.72
Enterprise Value
$151.81 M
EV / EBITDA
-1.93
EV / Revenue
4.91
Rating
Strong Buy
Target Price
$11.44
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 2. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 3. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 4. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 5. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 6. | Atea Pharmaceuticals, Inc. | $5.71 | — | $457.32 M | — | -65.67% | -44.34% | $6.45 / $2.46 | $3.52 |
| 7. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 9.25 M | 8.15 M | 7.56 M | 5.95 M | 2.86 M | — |
| Operating Profit | -19.6 M | -18.5 M | -21.1 M | -22.91 M | -24 M | — |
| Net Profit | -21.66 M | -15.85 M | -17.94 M | -18.83 M | -19.5 M | — |
| EPS in Rs | -0.37 | -0.27 | -0.31 | -0.32 | -0.33 | -0.31 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 30.91 M | 22.6 M | 34.16 M | 19.23 M |
| Operating Profit | -82.11 M | -100.28 M | -107.91 M | -117.14 M |
| Net Profit | -74.28 M | -86.62 M | -98.43 M | -108.88 M |
| EPS in Rs | -1.27 | -1.48 | -1.68 | -1.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 198.1 M | 283.98 M | 285.92 M | 404.88 M |
| Total Liabilities | 306.6 M | 329.51 M | 363.11 M | 404.77 M |
| Equity | -108.5 M | -45.53 M | -77.19 M | 0.11 M |
| Current Assets | 163.24 M | 249.6 M | 240.18 M | 351.4 M |
| Current Liabilities | 59.74 M | 66.99 M | 58.44 M | 55.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -86.1 M | -100.41 M | -118.11 M | 193.61 M |
| Investing CF | 112.04 M | -29.9 M | 144.45 M | -244.32 M |
| Financing CF | 1.02 M | 105.43 M | 1.78 M | 1.76 M |
| Free CF | -86.15 M | -101.31 M | -119.33 M | 192.4 M |
| Capex | -0.05 M | -0.91 M | -1.22 M | -1.21 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -33.83% | 77.63% | — | — |
| Earnings Growth % | 11.99% | 9.6% | — | — |
| Profit Margin % | -383.24% | -288.17% | -566.27% | — |
| Operating Margin % | -443.7% | -315.93% | -609.2% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -429.9% | -305.83% | -591.93% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.